EU Lead Factory (ELF) and CELLIPSE announced today completion of the 1st phase of their collaboration program to identify hits against an undisclosed innovative therapeutic target that is involved in cytoskeleton regulation.
The qualified hit list delivered to CELLIPSE was obtained from a screening program on ELF’s Joint European Compound Library that included more than 400,000 (now 450,000) compounds. The screening effort was led by Pivot Park Screening Centre, with support from the University of Oxford, University of Dundee, Newhouse and CELLIPSE.
During the 57th American Society of Hematology Congress held in Orlando, the teams from U. of Indiana Wells Center led by Pr Kapur and Institut Albert Bonniot led by Dr Lafanechère presented the results of their work in the session dedicated to Oncogene and Tumor Suppressors in Myeloïd malignancies. This new data reinforces the rationale for looking into LIM Kinase inhibition to stop downstream oncogene signaling of specific mutations of Tyrosine Kinase Receptors.